公开(公告)号：US20230128132A1

公开(公告)日：2023-04-27

申请号：US18085869

申请日：2022-12-21

Applicant: Arvinas Operations, Inc.

Inventor： Andrew P. CREW ,  Lawrence B. SNYDER ,  Jing WANG ,  Royal J. HASKELL, III ,  Marcia Dougan MOORE

IPC: A61K31/501 ,  A61P35/00 ,  A61K9/00

Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.

公开(公告)号：US20220193072A1

公开(公告)日：2022-06-23

申请号：US17548842

申请日：2021-12-13

Applicant: Arvinas Operations, Inc.

Inventor： Xin CHEN ,  Andrew P. CREW ,  John FLANAGAN ,  Sheryl Maxine GOUGH ,  Royal J. HASKELL, III ,  Marcia Dougan MOORE ,  Yimin QIAN ,  Ian Charles Anthony TAYLOR ,  Jing WANG

IPC: A61K31/497 ,  A61P35/04 ,  A61K31/519

Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.

公开(公告)号：US20210113557A1

公开(公告)日：2021-04-22

申请号：US17075808

申请日：2020-10-21

Applicant: Arvinas Operations, Inc.

Inventor： Andrew P. CREW ,  Lawrence B. SNYDER ,  Jing WANG ,  Royal J. HASKELL, III ,  Marcia Dougan MOORE

IPC: A61K31/501 ,  A61P35/00 ,  A61K9/00

Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4 and n are defined herein.

公开(公告)号：US20250120968A1

公开(公告)日：2025-04-17

申请号：US18988049

申请日：2024-12-19

Applicant: Arvinas Operations, Inc.

Inventor： Xin CHEN ,  Andrew P. CREW ,  John FLANAGAN ,  Sheryl Maxine GOUGH ,  Royal J. HASKELL, III ,  Marcia Dougan MOORE ,  Yimin QIAN ,  Ian Charles Anthony TAYLOR ,  Jing WANG

IPC: A61K31/496 ,  A61K31/519 ,  A61K47/02 ,  A61K47/22 ,  A61K47/26 ,  A61K47/38 ,  A61P35/00

Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.

公开(公告)号：US20210060008A1

公开(公告)日：2021-03-04

申请号：US17001519

申请日：2020-08-24

Applicant: Arvinas Operations, Inc.

Inventor： Xin CHEN ,  Andrew P. CREW ,  John FLANAGAN ,  Sheryl Maxine GOUGH ,  Royal J. HASKELL, III ,  Marcia Dougan MOORE ,  Yimin QIAN ,  Ian Charles Anthony TAYLOR ,  Jing WANG

IPC: A61K31/496 ,  A61K47/38 ,  A61K47/26 ,  A61K47/02 ,  A61K47/22 ,  A61K31/519 ,  A61P35/00

Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.